Downregulation of yidC in Escherichia coli by Antisense RNA Expression Results in Sensitization to Antibacterial Essential Oils Eugenol and Carvacrol

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Patil, Supriya Deepak ^a   Sharma, Rajnikant ^a   Srivastava, Santosh ^a   Navani, Naveen Kumar ^a   Pathania, Ranjana ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CARVACROL; COLISTIN; COMPLEMENTARY RNA; ESSENTIAL OIL; EUGENOL; FOSFOMYCIN; KANAMYCIN; MESSENGER RNA; MITOMYCIN; NOVOBIOCIN; POLYMYXIN B; TETRACYCLINE; TRICLOSAN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ESCHERICHIA COLI; ESSENTIAL GENE; EXPRESSION VECTOR; GENE SILENCING; GROWTH INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; YIDC GENE;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; EUGENOL; GENE EXPRESSION REGULATION, BACTERIAL; GENE SILENCING; GENES, ESSENTIAL; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MONOTERPENES; OILS, VOLATILE; RNA, SMALL INTERFERING;

EID: 84874604421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057370     Document Type: Article

References (42)

1. Davies J, (2007) Microbes have the last word. A drastic re-evaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria. EMBO reports 8: 616.
2. Miesel L, Greene J, Black TA, (2003) Genetic strategies for antibacterial drug discovery. Nature Reviews Genetics 4: 442-456.
3. Roemer T, Davies J, Giaever G, Nislow C, (2011) Bugs, drugs and chemical genomics. Nature Chemical Biology 8: 46-56.
4. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr JE, (2004) Trends in antimicrobial drug development: implications for the future. Clinical Infectious Diseases 38: 1279-1286.
5. Vergidis PI, Falagas ME, (2008) Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Current opinion in investigational drugs (London, England: 2000) 9: 176.
6. Xu HH, Trawick JD, Haselbeck RJ, Forsyth R, Yamamoto RT, et al. (2010) Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials. Antimicrobial agents and chemotherapy 54: 3659-3670.
7. Pathania R, Brown ED, (2008) Small and lethal: searching for new antibacterial compounds with novel modes of action. Biochemistry and Cell Biology 86: 111-115.
8. Moir DT, Opperman TJ, Butler MM, Bowlin TL (2012) New classes of antibiotics. Current Opinion in Pharmacology.
9. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang C, et al. (2006) Discovery of FabH/FabF inhibitors from natural products. Antimicrobial agents and chemotherapy 50: 519-526.
10. Nakashima N, Tamura T, Good L, (2006) Paired termini stabilize antisense RNAs and enhance conditional gene silencing in Escherichia coli. Nucleic acids research 34: e138-e138.
11. Massé E, Escorcia FE, Gottesman S, (2003) Coupled degradation of a small regulatory RNA and its mRNA targets in Escherichia coli. Genes & development 17: 2374-2383.
12. Dryselius R, Aswasti SK, Rajarao GK, Nielsen PE, Good L, (2003) The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli. Oligonucleotides 13: 427-433.
13. Knudsen H, Nielsen PE, (1996) Antisense properties of duplex-and triplex-forming PNAs. Nucleic acids research 24: 494-500.
14. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, et al. (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proceedings of the National Academy of Sciences 104: 7612-7616.
15. Wang J, Soisson SM, Young K, Shoop W, Kodali S, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
16. Boberek JM, Stach J, Good L, (2010) Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PloS one 5: e13745.
17. Projan SJ, (2002) New (and not so new) antibacterial targets-from where and when will the novel drugs come? Current Opinion in Pharmacology 2: 513.
18. Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ, (2002) Novel antibacterials: a genomics approach to drug discovery. Current Drug Targets-Infectious Disorders 2: 291-308.
19. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2006) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery 6: 29-40.
20. Scotti PA, Urbanus ML, Brunner J, de Gier JWL, von Heijne G, et al. (2000) YidC, the Escherichia coli homologue of mitochondrial Oxa1p, is a component of the Sec translocase. The EMBO journal 19: 542-549.
21. Serek J, Bauer-Manz G, Struhalla G, Van Den Berg L, Kiefer D, et al. (2004) Escherichia coli YidC is a membrane insertase for Sec-independent proteins. The EMBO journal 23: 294-301.
22. Samuelson JC, Chen M, Jiang F, Möller I, Wiedmann M, et al. (2000) YidC mediates membrane protein insertion in bacteria. Nature 406: 637-641.
23. van der Laan M, Urbanus M, Ten Hagen-Jongman C, Nouwen N, Oudega B, et al. (2003) A conserved function of YidC in the biogenesis of respiratory chain complexes. Proceedings of the National Academy of Sciences 100: 5801.
24. Hasona A, Crowley PJ, Levesque CM, Mair RW, Cvitkovitch DG, et al. (2005) Streptococcal viability and diminished stress tolerance in mutants lacking the signal recognition particle pathway or YidC2. Proceedings of the National Academy of Sciences of the United States of America 102: 17466-17471.
25. Zhang YJ, Tian HF, Wen JF, (2009) The evolution of YidC/Oxa/Alb3 family in the three domains of life: a phylogenomic analysis. BMC evolutionary biology 9: 137.
26. Prabuseenivasan S, Jayakumar M, Ignacimuthu S, (2006) In vitro antibacterial activity of some plant essential oils. BMC Complementary and Alternative Medicine 6: 39.
27. Ouattara B, Simard RE, Holley RA, Piette GJP, Bégin A, (1997) Antibacterial activity of selected fatty acids and essential oils against six meat spoilage organisms. International journal of food microbiology 37: 155-162.
28. Gill A, Holley R, (2006) Inhibition of membrane bound ATPases of Escherichia coli and Listeria monocytogenes by plant oil aromatics. International journal of food microbiology 111: 170-174.
29. Donald RGK, Skwish S, Forsyth R, Anderson JW, Zhong T, et al. (2009) A Staphylococcus aureus Fitness Test Platform for Mechanism-Based Profiling of Antibacterial Compounds. Chemistry & biology 16: 826-836.
30. Goh S, Boberek JM, Nakashima N, Stach J, Good L, (2009) Concurrent growth rate and transcript analyses reveal essential gene stringency in Escherichia coli. PloS one 4: e6061.
31. Kim BC, Gu MB, (2006) Expression analysis of stress-specific responsive genes in two-stage continuous cultures of Escherichia coli using cDNA microarray and real-time RT-PCR analysis. Enzyme and microbial technology 39: 440-446.
32. Meng J, Kanzaki G, Meas D, Lam CK, Crummer H, et al. (2012) A genome-wide inducible phenotypic screen identifies antisense RNA constructs silencing Escherichia coli essential genes. FEMS Microbiology Letters.
33. Odds F, (2003) Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy 52: 1-1.
34. Dryselius R, Nikravesh A, Kulyté A, Goh S, Good L, (2006) Variable coordination of cotranscribed genes in Escherichia coli following antisense repression. BMC microbiology 6: 97.
35. Ji Y, Yin D, Fox B, Holmes DJ, Payne D, et al. (2006) Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiology Letters 231: 177-184.
36. Forsyth R, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, et al. (2002) A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Molecular microbiology 43: 1387-1400.
37. Olano C, Lombó F, Méndez C, Salas JA, (2008) Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metabolic engineering 10: 281-292.
38. Burt S, (2004) Essential oils: their antibacterial properties and potential applications in foods-a review. International journal of food microbiology 94: 223-253.
39. Dryselius R, Nekhotiaeva N, Good L, (2005) Antimicrobial synergy between mRNA-and protein-level inhibitors. Journal of Antimicrobial Chemotherapy 56: 97-103.
40. Kahan FM, Kahan JS, Cassidy PJ, Kropp H, (2006) The mechanism of action of fosfomycin (phosphonomycin). Annals of the New York Academy of Sciences 235: 364-386.
41. Pathania R, Zlitni S, Barker C, Das R, Gerritsma DA, et al. (2009) Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nature Chemical Biology 5: 849-856.
42. Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE, (2001) Bactericidal antisense effects of peptide-PNA conjugates. Nature biotechnology 19: 360-364.